Daratumumab is an anticancer drug that binds to the CD38 protein overexpressed in multiple myeloma cells, causing immune-mediated apoptosis of the tumor cell. The new variety of anti-daratumumab antibodies makes up three fully human IgG1 repressive antibodies with differing levels of affinity. The antibodies are perfect for usage as surrogate positive controls in anti-drug antibody assays, and for the advancement of pharmacokinetic bridging ELISAs to determine complimentary drug. Bio-Rad offers a portfolio of recombinant, monoclonal, nonanimal-derived anti-idiotypic antibodies and drug– target complex binders for the development of highly selective and delicate assays. These critical reagents enable scientists to establish robust techniques in a short timescale and produce translatable and reproducible outcomes. The antibodies are produced using the Human Combinatorial Antibody Libraries (HuCAL ® )and CysDisplay ®, a proprietary approach of phage display, in addition to directed selection techniques to acquire extremely targeted reagents We are pleased to continue the expansion of our variety of anti-idiotypic antibodies to support researchers developing novel treatments”; said Amanda Turner, Bio-Rad Product Manager, Life Science Group. Our recombinant production techniques result in batch-to-batch consistency, so scientists can count on our antibodies to deliver reproducible outcomes over the lifecycle of their bioanalytical assays” she said. The anti-daratumumab antibodies are authorized for in vitro research study purposes and for business applications providing in vitro testing services to support preclinical and clinical drug advancement. To find out more about Bio-Rads anti-daratumumab antibodies, please visit https://www.bio-rad-antibodies.com/anti-daratumumab-antibody-darzalex.htmlAbout Bio-RadBio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a worldwide leader in establishing, producing, and marketing a broad series of ingenious products for the life science research study and medical diagnostic markets. With a focus on quality and customer care for 70 years, our items advance the discovery process and enhance health care. Our customers are university and research study institutions, healthcare facilities, public health and business labs, and biotechnology and pharmaceutical business, along with used laboratories that consist of food safety and ecological quality. Established in 1952, Bio-Rad is based in Hercules, California, and has a global network of operations with more than 7,800 workers worldwide. Bio-Rad had revenues exceeding $2.5 billion in 2020.
